Psychedelic Pharmacology by Substance

 

Go Deep with a Comprehensive Look at the Science and Clinical Data Behind Each Molecule in the Psychedelic Psychopharmacology Master Series Second Course 

"As a Board Certified Psychiatric Pharmacist I aim to create high quality and evidence-based educational materials advocating for safe, beneficial, and empowered use of Psychedelic Therapies" 

- Dr. Ben Malcolm, PharmD, MPH

 

Course Modules &  Learning Objectives

Psychedelic Pharmacology by Substance

 

MDMA

  • Describe pharmacological properties of MDMA
  • Summarize clinical research results of MDMA-assisted psychotherapy (MDMA-AP)
  • Discuss harm reduction and the toxicity profile of MDMA
  • Outline drug interactions associated with MDMA

Psilocybin

  • Describe pharmacological properties of psilocybin
  • Summarize clinical research results of psilocybin-assisted psychotherapy (Psilocybin-AP)
  • Discuss the toxicity profile of psilocybin
  • Outline drug interactions associated with psilocybin

LSD

  • Describe pharmacological properties of Lysergic Acid Diethylamide (LSD)
  • Discuss the toxicity profile of LSD
  • Outline drug interactions associated with LSD
  • Summarize recent neuroscientific research results of LSD on brain function

Mescaline

  • Discuss Peyote and why little clinical research is being conducted with mescaline today
  • Describe pharmacologic properties of mescaline
  • Compare and contrast the pharmacology of mescaline with classic tryptamine psychedelics (LSD, psilocybin, and DMT) and synthetic phenethylamine psychedelics (MDMA)

Ayahuasca & MAOIs

  • Describe pharmacological properties of harmala alkaloids in ayahuasca
  • Define adverse reactions associated with food and dietary interactions with ayahuasca such as hypertensive crisis and serotonin syndrome
  • Formulate management strategies to avoid adverse reactions from interacting foods and drugs
  • Summarize observational, clinical, and toxicologic studies relating to ayahuasca use

DMT & 5-MeO-DMT

  • Describe and compare the pharmacology of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
  • Explain why 5-MeO-DMT is dangerous in conjunction with MAOIs whereas DMT is not
  • Summarize clinical and observational research relating to DMT and 5-MeO-DMT

Ketamine

  • Describe pharmacological properties of ketamine
  • Summarize clinical data relating to uses of ketamine in psychiatry
  • Discuss the toxicity profile of ketamine
  • Outline drug interactions associated with ketamine

Ibogaine

  • Describe pharmacological properties of Ibogaine
  • Discuss ibogaine-induced cardiotoxicity
  • List contraindicated drugs and conditions with ibogaine
  • Summarize clinical research results using ibogaine to manage substance use disorders

Knowledge assessments for each substance with over 50 questions to test your knowledge of materials presented in Psychedelic Pharmacology by Substance

Knowledge Assessments

Two Ways to Access the Course!

Enroll today and get started building your knowledge of psychedelic substances with Psychedelic Pharmacology by Substance

Lifetime access $297

When you enroll in the Psychedelic Pharmacology by Substance course, you'll enjoy being able to come back to course materials forever

Membership $99/m

Join the membership for access to my courses, live monthly summits, psychedelic drug interaction guides, and discounted consultation services

Enroll Today
Join and Access

Why the Psychedelic Pharmacology Master Series?

It took me 15 years of formal education, post-graduate training, and research conducted independently to gain the knowledge, experience, and skills I needed to construct the educational materials I present in the Psychedelic Psychopharmacology Master Series. 

 

I had to seek information from a patchwork of places over a long period of time and essentially embark on a circuitous educational journey to get to where I am now.

 

Psychedelic research has exploded and we will need a fully functioning fleet of educated professionals to safely implement and harness the tremendous therapeutic potential of these substances and avoid repeating the mistakes of the past. 

 

I sincerely believe that I could have learned what I know now about psychedelics in a much shorter period of time if I had the materials I compiled for the psychedelic pharmacology master series.

 

My aim is to catalyze your foundation for understanding psychedelic science by laying the educational bedrock for cultures focused on safe psychedelic use.

 

The Psychedelic Pharmacology Master Series helps learners all over the world grow into the roles they are destined to play in the psychedelic renaissance at an accelerated rate.